HCPCS Code Descriptor:
Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen
Route of Administration:
ANZEMET is an Oncology-Anti-Emetic drug manufactured by Sanofi and administered via the Oral route of administration. The Q Code: Q0180 is aligned to the drug ANZEMET.